AGRANULOCYTOSIS DURING CLOZAPINE THERAPY by Jagadheesan, K. et al.
LETTERS TO EDITOR 
One might, perhaps, have forgive the 
a inaccuracies had the story appeared in small 
circulation newpaper of little repute. But, the story 
had earlier been published in the prestigious 
Story Quarterly, and later in the Pulitzer Prize-
winning book. The interpretation of maladies has 
truly been misinterpretation. 
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DO INDIAN RESEARCHERS READ INDIAN 
RESEARCH? A REAPPRAISAL, FOUR 
YEARS LATER 
Sir, 
This is in response to the article' Do Indian 
researchers read Indian research? a reappraisal, 
four years later', published in April 2000 (No.2, 
f Vol.42) issue of your journal. The authors of this 
article have documented their observations on 
my article 'Transsexualism in Schizophrenia : a 
case report' (April, 1998, Vol.40, No.2) that I did 
not refer to their article, 'Behaviour Therapy for 
Trans-sexualism' (July,1995, Vol.37, No.3) in 
my paper. The authors cited this case as an 
example of the fact that Indian (Psychiatric) 
Researchers do not read Indian (Psychiatric) 
Research Published in Indian Journal of 
Psychiatry. 
Without going through the contents of my 
article, the authors seem to have concluded that 
an article on transsexualism must be referenced 
in all subsequent publications on transsexualism 
irrespective of its relevance. This article in 
question deals with the treatment of 
transsexualism with behaviour therapy while my 
paper is a case report on transsexualism with 
schizophrenia with the focus of the article being 
entirely on manifestation of transsexualism in 
the setting of schizophrenia or psychosis. Not 
only I did not refer to the authors' above 
mentioned "Indian" article, I also did not refer to 
several other "not-Indian" articles on 
transsexualism. The focus of both the articles is 
different and I did not find it appropriate to 
mention that article in my paper through I am 
well aware of its publication. Authors should have 
done some home work before reaching their 
conclusion This reflects how much authors 
themselves read Indian research. Indian Journal 
of Psychiatry is a valued possession for its 
readers and no one can take liberty to play with 
their sentiments by their irresponsible writings. 
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AGRANULOCYTOSIS DURING CLOZAPINE 
THERAPY 
Sir, 
Agranulocytosis, defined as granulocyte 
count less than 500-cells/mm\ is a serious 
complication of clozapine therapy It occurs 
frequently in the first three months and 95% 
cases occur within the first six months of 
treatment (Young et al.,1998). Its one-year 
cumulative incidence is 0.8% (Alvir et al.,1993). 
This complication has no relation with clozapine 
dose and presently, it is difficult to predict who 
will develop it (Honigfeld et al., 1998) In contrast 
to the Western literature, only one case of 
clozapine-induced agranulocytosis has been 
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reported in the Indian counterpart (Srinivasan & 
Thomas,1998). We report another case of 
agranulocytosis 
A 26 years old man, introvert premorbidly, 
was admitted with the ICD-10 (World Health 
Organization, 1992) diagnosis of undifferentiated 
schizophrenia of seven years. One of his second-
degree relative had an unspecified mental 
illness. Following hospitalization, clozapine was 
started in view of poor prior response to 
conventional antipsychotics. It was gradually 
increased to 600 mg/day. Baseline blood studies 
were within normal limits except raised total 
WBC counts (12,400-cells/mm
3). Medical history 
and examination failed to reveal any disorder 
that might have presented with leukocytosis. 
Consequent to EEG showing 16 episodes of 
generalized spike, polyspike and wave 
complexes lasting 200-1200 m.sec in a 30 
minutes record, sodium valproate was started 
at 12th week and titrated to 800 mg/day. Patients' 
hematological profile was done regularly 
revealing the following results. With few 
fluctuations, his eosinophils count steadily 
increased from 7% (623 cells/mm
3) at second 
week after starting clozapine to a maximum of 
40% (6360 cells/mm
3) at 16th week. No allergies 
or any eosinophilia related disorder were found 
on examination or in history, however, he was 
empirically given two doses of albendazole (400 
mg) at 14th and 15th weeks. Meanwhile, total 
WBC count fluctuated between 6,200 and 11,900 
cells/mm
3 up to 13th week, from when it 
increased to its maximum (15,900 cells/mm
3) at 
16th week Soon afterward, it suddenly dropped 
to 8,500 cells/mm
3 (neutrophils: 52%, 4240 cells/ 
mm
3) at 17th week and to 1,300 cells/mm
3 
(neutrophils: 18%, 234 cells/mm
3) at 18th week. 
Concurrently he developed pyrexia (39°C) and 
all the drugs were immediately discontinued. 
Following an urgent physician consultation, along 
with reverse isolation, broad-spectrum antibiotics 
were started. Since there were practical 
difficulties in acquiring granulocyte-colony-
stimulating factor (G-CSF), lithium 300 mg/day, 
in view of its WBC count increasing property, 
was started. He gradually improved and the total 
WBC count, on the fourth day of conservative 
management, was4,500-cells/mm
3 (neutrophils ) 
count of 630-cells/mm
3). 
This patient was on clozapine and sodium 
valproate at the onset of WBC decline. An 
association between sodium valproate and 
neutropenia was reported earlier (Symon & 
Russel,1983); however, its association with 
agranulocytosis is unknown. Presently, sodium 
valproate is considered as the agent of first 
choice in the management of clozapine-induced 
seizures (Young et al.,1998). Due to these 
reasons, we considered clozapine but not sodium 
valproate as the causative agent for 
agranulocytosis. 
Our patient had no known risk factors of 
agranulocytosis such as female sex, increased 
age and age less than 21 years (Alviretal., 1993; 
Alvir & Liberman, 1994). A notable finding in this 
patient was persisting eosinophilia that peaked 
just before the onset of WBC decline. This is an 
interesting phenomenon given the fact that an 
association has been noted between clozapine- i 
induced eosinophilia and neutropenia (Galletly 
et al.,1996; Lucht & Rietchel, 1998). Since 
eosinophilia has higher incidence rate (Hummer 
et al., 1994) and all patients with eosinophilia do 
not develop either neutropenia or 
agranulocytosis, we could not explain the 
significance of eosinophilia. There are 
possibilities of influence of some intervening 
factors, hence, we suggest that other factors that 
might precipitate agranulocytosis, in the 
presence of eosinophilia, should be investigated. 
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RISPERIDONE-INDUCED OCULOGYRIC 
CRISIS 
Sir, 
Risperidone in low doses (< 6 mg) is 
reported to be relatively free from extrapyramidal 
side effects including dystonia, akathisia, drug-
induced parkinsonism and tardive dyskinesia 
(Thomas and Lewis, 1998). A double blind study, 
which included 388 schizophrenic patients drawn 
from 20 sites in the United States, reported that 
the incidence of extrapyramidal symptoms in 
patients receiving 6 mg of risperidone was no 
higher than that in patients receiving placebo 
(Marder and Meibach.1994) To our knowledge, 
few cases of dystonic reactions and one case of 
oculogyric crisis (OGC) as part of the dystonic 
reaction during risperidone treatment have been 
reported in the literature (Dickson et al.,1994; 
Radford et al.,1995; Faulk et al ,1996). We report 
two patients with schizophrenia who developed 
OGC crises during risperidone treatment 
Case 1: Ms. A, a 22-year-old girl with 
DSM-IV paranoid schizophrenia for 8 months 
was hospitalised and treatment was initiated in 
the form of risperidone 1 mg bid on first day 
and 2 mg bid. from second day onwards Patient 
did not receive any concomitant medication 
except lorazepam 2 mg h.s. After four days of 
treatment with risperidone, Ms A started having 
repeated episodes of upward deviation and 
fixation of eyeballs, with no other associated 
dystonic reaction, which would be relieved after 
giving promethazine, 25 mg i.m. Tablet 
trihexyphenidyl 2 mg t.id. was added which 
successfully prevented these episodes 
Case 2: Mrs. S, a 40-year-old lady with 
DSM-IV undifferentiated schizophrenia for 17 
years presented with prominent negative 
symptoms. During 17 years of her illness, she 
received trials of various antipsycotics including 
chlorpromazine, haloperidol, trifluoperazine and 
fluphenazme decanoate without significant 
improvement in negative symptoms After 
hospitalisation, previous medications were 
gradually discontinued and risperidone was 
started with gradual dosage increment, i.e. 1 mg 
bid on first day, 2mg bid on second day and 
3 mg bid then on. On the sixth day of treatment, 
she developed episodes of upward fixed gaze, 
which used to subside on giving promethazine, 
25mg i.m. The frequency of such episodes did 
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